SCHEMBL4091384

SCHEMBL4091384

CCCCNS(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.64
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
MAPT P10636 3/20 0.64
GAA P10253 2/20 0.64
RAB9A P51151 1/20 0.59
CA1 P00915 3/20 0.57
CA2 P00918 3/20 0.57
CA12 O43570 1/20 0.57
CA3 P07451 1/20 0.57
CA4 P22748 1/20 0.57
CA6 P23280 1/20 0.57
CA5A P35218 1/20 0.57
CA7 P43166 1/20 0.57
CA9 Q16790 1/20 0.57
CA13 Q8N1Q1 1/20 0.57
CA14 Q9ULX7 1/20 0.57
CA5B Q9Y2D0 1/20 0.57
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10571075 0.94 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL3685056 0.90 MEN1 (0.62) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL7040461 0.89 MEN1 (0.56) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL7042308 0.86 MEN1 (0.56) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL7038862 0.86 MEN1 (0.53) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL7392876 0.84 ALDH1A1 (0.62) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL27911508 0.84 MAPT (0.62) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL2034554 0.84 KMT2A (0.78) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL7042796 0.84 USP2 (0.65) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL12631870 0.83 MAPK1 (0.66) ALDH1A1MEN1KMT2AMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719413-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF Animol Discovery, Inc. (US) 2026-04-08 EP disclosed
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY INC (US) 2026-04-02 US disclosed
WO-2024246837-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY, INC. (US) 2024-12-05 WO disclosed
CN-110194738-B Preparation method of 1,2, 3-trisubstituted 4-quinolone derivative 华侨大学 2022-04-05 CN disclosed
US-9994728-B2 Photosensitive resin composition and color filter using the same SAMSUNG SDI CO., LTD. (KR) 2018-06-12 US disclosed
US-20160152654-A1 TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-06-02 US disclosed
US-20160090501-A1 Photosensitive Resin Composition and Color Filter Using the Same SAMSUNG SDI CO., LTD. (KR) 2016-03-31 US disclosed
US-20160090501-A1 Photosensitive Resin Composition and Color Filter Using the Same SAMSUNG SDI CO., LTD. (KR) 2016-03-31 US disclosed
US-8828631-B2 Pigment dispersion composition, photosensitive resin composition including the same and color filter using the same CHEIL INDUSTRIES INC. (KR) 2014-09-09 US disclosed
US-8828631-B2 Pigment dispersion composition, photosensitive resin composition including the same and color filter using the same CHEIL INDUSTRIES INC. (KR) 2014-09-09 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed
US-5783699-A MAY BE CONJUGATED TO ANTIGENS, HAPTENS, ANTIBODIES IN IMMUNOASSAYS ABBOTT LABORATORIES (US) 1998-07-21 US disclosed
US-5669819-A IMMUNOASSAY ABBOTT LABORATORIES (US) 1997-09-23 US disclosed
US-5565570-A REACTING AMINE WITH SULFONYL HALIDE IN INERT SOLVENT IN PRESENCE OF BASE TO FORM METAL SALT OF SULFONAMIDE, ACYLATING WITH ACTIVATED PHENANTHRIDINE-6-CARBOXYLIC ACID TO FORM CHEMILUMINESCENT SALT ABBOTT LABORATORIES (US) 1996-10-15 US disclosed
US-5545739-A E.G., 5-METHYL-6-(N-2-CARBOXYETHYL-N=(2-CARBOXYETHYL)-PHENANTHRIDIN IUMCARBOXAMIDE CHLORIDE; IMMUNOASSAYS; STABILITY; SENSITIVITY ABBOTT LABORATORIES (US) 1996-08-13 US disclosed
US-5543524-A FORMING A SULFONAMIDE FROM AND AMINE AND A SULFONYL HALIDE AND AND ACYLATING WITH A CARBONYL HALIDE OF AN ACTIVATED ACRIDINE SALT ABBOTT LABORATORIES (US) 1996-08-06 US disclosed
US-5468646-A Chemiluminescent acridinium salts ABBOTT LABORATORIES (US) 1995-11-21 US disclosed
EP-0273115-B1 Chemiluminescent acridinium and phenanthridinium salts ABBOTT LAB (US) 1994-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR ALDH1A1 3968/4885MEN1 2079/4885KMT2A 3304/4885
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF JAK1, JAK3, JAK2 ALDH1A1 1691/4885MEN1 4190/4885KMT2A 1056/4885
US-20160152654-A1 TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME PROKR1, ARG1, ARG2 ALDH1A1 1300/4885MEN1 1170/4885KMT2A 3823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.